Long-expected UK layoffs imminent for Novartis following sale
Nearly a year ago, more than 200 workers at Novartis’ Grimsby, UK, facility were able to hang on to their jobs after the pharma closed a Switzerland site as a part of its workforce restructuring plan. Now, it looks like those employees’ time is up, as the site has been sold, Grimsby Telegraph reported today.
The manufacturing site has been sold to Humber Industrials, a subsidiary of International Process Plants. None of the current staff members will be working with the new owners, however.
Novartis previously has said that it will wait until late 2022 to formally close the site, which currently produces two products. The pharma originally announced plans to close the site in 2018, putting hundreds of employees on the chopping block. Those plans were delayed for a year after Novartis instead chose to close one of three buildings on site.
But two years later, more than 100 employees left that facility, which has run continuously for 71 years, BusinessLive reported. The site is estimated to contribute around $32.5 million to its local workforce each year.
The site, which sits on Moody Lane, takes up 229-acres of land, though Novartis will gift 35 of those acres to North East Lincolnshire as a part of an ‘environmental legacy,” Grimsby Telegraph reported.
IPP is based out of New Jersey, and has an office in Billingham, Teesside. Novartis will continue its manufacturing for the next few months, before the transfer is completed.
These cuts come on top of a proposed 2,200 jobs that will be eliminated in its home country of Switzerland alone. That includes 1,500 staff at production facilities it runs in Basel, Stein, Locarno and Schweizerhalle, while 700 service jobs in Basel — which is home — are being redistributed to one of five global centers in Dublin, Hyderabad, Kuala Lumpur, Mexico City and Prague.